Neuroscience News and Research

RSS

Wellcome-Wolfson Capital Awards initiative invests over 30M in large-scale university infrastructure projects

Over -30 million is being invested into large-scale university infrastructure projects courtesy of the Wellcome-Wolfson Capital Awards initiative.

3 Jul 2010

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement (as measured by glycosylated hemoglobin level (HbA1c)) in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.

2 Jul 2010

Research may provide key to understanding interplay between exercise, aging and neurogenesis

Stem cells in the brain remain dormant until called upon to divide and make more neurons. However, little has been known about the molecular guards that keep them quiet.

2 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

Euthymics and DOV sign merger agreement

Euthymics Bioscience, Inc., a privately held Delaware corporation, and DOV Pharmaceutical, Inc., a Delaware corporation currently traded on the Pink Sheets, today jointly announced that they have signed a merger agreement in connection with the pending merger and acquisition of DOV by Euthymics.

1 Jul 2010

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Andrew Lees, Professor of Neurology at University College London, is to be the first ever recipient of the Lord Brain Memorial Medal - awarded for the scientific contributions he has made to the field of movement disorders within the UK. He will receive the medal following his delivery of the inaugural Lord Brain Memorial Lecture; "Brainwashed by the Black Stuff," at Barts and The London Medical School on June 24, 2010.

1 Jul 2010

Brain is intrinsically unreliable, says new research

Next time your brain plays tricks on you, you have an excuse: according to new research by UCL scientists published today in the journal Nature, the brain is intrinsically unreliable.

1 Jul 2010

New research identifies memory and brain scan as best tests for predicting Alzheimer's disease

New research has identified the memory and brain scan tests that appear to predict best whether a person with cognitive problems might develop Alzheimer's disease. The research is published in the June 30, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

1 Jul 2010

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

1 Jul 2010

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.

1 Jul 2010

Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression

Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.

1 Jul 2010

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

For the first time, scientists have linked a brain compound called kynurenic acid to cognition, possibly opening doors for new ways to enhance memory function and treat catastrophic brain diseases, according to a new study from the University of Maryland School of Medicine. When researchers decreased the levels of kynurenic acid in the brains of mice, their cognition was shown to improve markedly, according to the study, which was published in the July issue of the journal Neuropsychopharmacology.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

Integra LifeSciences VP honored as Fellow of the American Academy of Nursing

Integra LifeSciences Holdings Corporation announced today that Linda Littlejohns RN MSN CCRN CNRN, Vice President, Clinical Development at Integra, has been selected as a Fellow of the American Academy of Nursing, one of the most prestigious nursing organizations in the country. The Academy's Fellows include many of the nation's top nursing executives, policymakers, scholars, researchers and practitioners.

30 Jun 2010

Study highlights importance of individualized, patient-centered therapies

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

30 Jun 2010

US District Court upholds validity and enforceability of CRESTOR patent

AstraZeneca announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 – the '314 patent) is valid and enforceable. In its ruling, the court found that no inequitable conduct was committed by any Shionogi employee. The court also held the '314 patent to be non-obvious and properly reissued.

30 Jun 2010

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to placebo plus insulin (with or without OADs).

29 Jun 2010

Researchers study mechanism of human brain

Because of its intricate organization, figuring out the wiring diagram that explains how the billions of neurons in the brain are connected, and determining how they work together, remains a formidable task.

29 Jun 2010

Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA

Astellas Pharma Inc. announced that the company presented results from a Japanese Phase 2 study conducted with ASP1941, a selective SGLT2 inhibitor, at the 70th Scientific Sessions of the American Diabetes Association (ADA) on June 26, 2010 (EST). ASP1941 is designed to block the re-absorption of glucose in the kidney and excrete glucose in the urine.

29 Jun 2010

Researchers use neonatal piglet model to study infant brain development

Events occurring during the development of an infant's brain can leave behind fingerprints. And researchers at the University of Illinois are interested in learning how these fingerprints can predict future behavioral problems such as cognitive deficits, anxiety disorders, depression, and even autism.

29 Jun 2010

Neuroscience News and Research

Wellcome-Wolfson Capital Awards initiative invests over 30M in large-scale university infrastructure projects

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Research may provide key to understanding interplay between exercise, aging and neurogenesis

AstraZeneca announces new support program for patients on ARIMIDEX

Euthymics and DOV sign merger agreement

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Brain is intrinsically unreliable, says new research

New research identifies memory and brain scan as best tests for predicting Alzheimer's disease

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Integra LifeSciences VP honored as Fellow of the American Academy of Nursing

Study highlights importance of individualized, patient-centered therapies

US District Court upholds validity and enforceability of CRESTOR patent

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Researchers study mechanism of human brain

Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA

Researchers use neonatal piglet model to study infant brain development

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News